tanruprubart
tanruprubart: 1 clinical trial tracked.
tanruprubart evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about tanruprubart, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (1)
An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of a Single Dose of Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (GBS) (FORWARD Study)
Primary endpoint: Area Under the Tanruprubart Serum Concentration-time Curve to the Last Sample (AUC0-t)
Interventionalopen30 targetStarted 2025-09Completion 2028-0613 sites · Denmark, United StatesAnnexon, Inc.